CoChat

Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first‐in‐human trials of high‐risk biologics

Open access
Agoram, Balaji M. · 2009 · British Journal of Clinical Pharmacology
Cited by 85

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Recent regulatory guidance has highlighted the importance of using pharmacokinetic–pharmacodynamic (PK–PD) modelling in the selection of starting doses in first‐in‐human trials of high‐risk biologics. • However, limited examples exist in literature illustrating this procedure. WHAT THIS STUDY ADDS • An interpretation of the recommended dose‐selection methodology and the minimum anticipated biological effect level (MABEL) principle, contained in the updated European Medicines Agency guidance on risk‐mitigation strategies for first‐in‐human studies, is presented. • Some literature and simulation‐based examples of the application of PK–PD modelling principles to starting dose selection using in vitro and in vivo data under the MABEL paradigm are highlighted, along with the advantages and limitations of this approach. AIMS To illustrate the use of pharmacokinetic–pharmacodynamic (PK–PD) models to select rational starting doses in clinical trials within the minimum anticipated biological effect level (MABEL) principle using literature data and through simulations. METHODS The new European Medicines Agency guidance on starting dose selection of high‐risk biologics was analysed considering the basic pharmacological properties and preclinical testing limitations of many biologics. The MABEL approach to dose selection was illustrated through simulations and through literature‐reported examples on the selection of starting doses for biologics such as antibodies based on in vitro biomarker data, in vivo PK and PK–PD data. RESULTS Literature reports indicating the use of preclinical pharmacological and toxicological data to select successfully safe starting doses in line with the MABEL principle are summarized. PK–PD model‐based simulations of receptor occupancy for an anti‐IgE antibody system indicate that the relative abundance of IgE in animal models and patients and the turnover rate of the IgE–antibody complex relative to the off‐rate of the antibody from IgE are important determinants of in vivo receptor occupancy. CONCLUSIONS Mechanistic PK–PD models are capable of integrating preclinical in vitro and in vivo data to select starting doses rationally in first‐in‐human trials. Biological drug–receptor interaction dynamics is complex and multiple factors affect the dose–receptor occupancy relationship. Thus, these factors should be taken into account when selecting starting doses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.2008.03297.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 85

Metadata

Authors
Agoram, B. M.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2009-02
Volume
67
Issue
2
Pages
153-160
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W2047805567
Cited by
85
References
2
FWCI
2.06
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first‐in‐human trials of high‐risk biologics. https://app.cochat.ai/papers/10.1111/j.1365-2125.2008.03297.x
The paper
Agoram, B. M. (2009). Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first‐in‐human trials of high‐risk biologics. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2008.03297.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.